GaryJRichmondMDFACP, FCCP

PubMed

• 51 citations
  Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase ...
  Hans Jaeger, Edgar T. Overton, Gary Richmond, Giuliano Rizzardini, Jaime Andrade-Villanueva
  The Lancet. HIV. 2021-11-01
• 12 citations
  Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression: pOLAR month 12 results.
  Anthony M. Mills, Gary Richmond, Cheryl L. Newman, Olayemi Osiyemi, Jerry Cade
  AIDS. 2021-10-13
• 21 citations
  Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATT...
  Graham H.R. Smith, W Keith Henry, Daniel Podzamczer, Maria Del Mar Masiá, Christopher J Bettacchi
  Open Forum Infectious Diseases. 2021-08-25

Journal Articles

• Effects of a Growth Hormone Releasing Factor Analogue on Body Composition and Metabolic Indices in HIV-Infected Patients.  
  Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Grinspoon S, New England Journal of Medicine
• Atrial Septal Rupture, Flail Tricupsid Valve, and Complete Heart Block Due to Nonpenetrating Chest Trauma.  
  Thors A, Guarneri R, Costantini G, Richmond G, Annals of Thoracic Surgery
• Recombinant Human Growth Hormone to Treat HIV-Associated Adipose Redistribution Syndrome: 12 Week Induction and 24-Week Maintenance Therapy.  
  Grunfeld C, Thompson M, Brown S, Richmond G, Lee D, Muurahainen N, Kotler D, Journal of Acquired Immune Deficiency Syndromes: JAIDS
• Pharmacokinetics, pharmacodynamics and safety of once-daily versus twice daily dosing with enfuvirtide in HIV-infected subjects.  
  Thompson M, DeJesus E, Richmond G, Wheeler D, Flaherty J, Piliero P, True A, Chiu U, Zhang Y, McFalls E, Miralles D, Patel I, AIDS
• T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimen.  
  Lalezari JP, Bellos NC, Sathasivam K, Richmond GJ, Cohen CJ, Myers RA Jr, Henry DH, Raskino C, Melby T, Murchison H, J. Infect Dis
• Pharmacodynamic Effects of Zidovudine 600 mg Once/Day Versus 300 mg Twice/Day in Therapy-Naïve Patients Infected with Human Immunodefiency Virus.  
  Ruane P, Richmond G, DeJesus E, Hill-Zabala C, Danehower S, Liao Q, Johnson J, Shaefer M, Pharmacotherapy
• Safety/Tolerability and Efficacy of Abacavir-Containing Combination Therapy in HIV-1 Infected Adults in a Clinical Practice Setting: Results of ZORRO.  
  Ruane P, Kubota M, Williams A, Arroyo J, Canas A, Richmond G, Alsop CA, Yau L, Hessenthaler S, Hernandez J, Infectious Diseases in Clinical Practice
• A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with Abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse tra...  
  Lalezari JP, DeJesus E, Northfelt DW, Richmond GJ, Wolfe P, Haubrich R, Henry D, Powderly W, Becker S, Thompson M, Valentine F, Wright D, Carlosn M, Riddler S, Haas FF..., Antiviral Therapy
• Twice Daily Amprenavir 1200 mg versus Amprenavir 600 mg / Ritonavir 100 mg in combination with at least 2 other antiretroviral drugs in HIV-1 infected patients.  
  Nadler JP, Gathe JC, Pollard RB, Richmond GJ, Liao Q, Griffith S, Lancaster T, Hernandez JE, Pappa KA, BMC Infectious Diseases
• HIV Patient Acceptance of a Needle-Free Device (SeroJet™) for Administering Recombinant Human Growth Hormone in the Treatment of HIV Infection-Associated Cachexia.  
  Murray FT, Muurahainen N, Gertner JM, Williams A, Santos G, Scheperle M, Richmond G, Findelstein J, Nebiolo L, Gaccione, P, Journal of New Developments in Clinical Medicine
• Primary Pulmonary Hypertension and HIV Infection in a Non-Hemophiliac Man.  
  Jacques C, Richmond G, Tierney L, Curtis J, McKerrow J, Warnock M, Human Pathology
• Superior venal caval syndrome: A Complication of Hickman Catheter Insertion in Patients with AIDS.  
  Richmond G, Handweger S, Schoenfeld N, Talavera W, New York State J. of Medicine
• On the Stability of IgE Antibodies.  
  Ovary Z, Itaya T, Santomauro J, Richmond G, J. Immunol. Methods
• Join now to see all

Abstracts/Posters

• A Week 48 Assessment of a Randomized, Controlled, Open-Label Phase II Trial (T20-206) Evaluating Three Doses of T-20 in PI-Experienced, NNRTI-Naïve Patients Infected w...
  Lalezari J, DeJesus E, Northfelt D, Richmond G, Delehanty J, Demasi R, Salgo M, 9th Conference on Retroviruses and Opportunistic Infections, Seattle WA
• Cardiovascular risk factors in patients with HIV-Associated Adipose Redistribution Syndrome (HARS).
  Grunfeld C, Brown S, Richmond G, Muurahainen N, Kotler D, 7th Internationsal Workshop on Adverse Drug Reactions and Lipodystrophy, Dublin, Ireland
• Efficacy and Tolerability of once daily doses of Reverset, a cytidine analog NRIT, in ARV-experienced patients. LB-1.
  Cohen C, Murphy R, Katlama C, Gathe J, Brinson C, Richmond G, Girard P, Fessel J, Liappis A, International AIDS Society Meeting, Buenos Ares, Argentina
• Once Daily Efavirenz Based Regimen for Treatment Naïve HIV Subjects: 96 Week Results from the DART II Trial.
  Dushyantha J, Sathasasivam K, Richmond G, Infectious Diseases Society of America (ISDA)
• Final analysis of T1249-102: T-1249 retains short term antiviral activity in patients who have failed a regimen containing enfuvirtide.
  Lalezari JP, Bellos N, Richmond G, Sathasivam K, Cohen C, Myers R, Henry D, Raskino C, Zhang Y, Spence B, Demasi R, Miralles D, 43rd ICAAC, Chicago IL
• Effect of r-hGH on Viral Load of Patients with HIV-associated Weight Loss on Highly Active Antiretrovial Theraply.
  Muurahainen N, Richmond G, Williams B, Witek J, Henry K, Oldfield E, Cure-Bolt N, Oliver C, 43rd ICAAC, Chicago IL
• Multiple-Dose Pharmacokinetics and Initial Antiviral Effect of Once Daily Lopinavir/Ritonavir in Combination with Tenofovir and Emtricitabine in HIV-Infected Antiretro...
  Chiu YL, Foit C, Gathe J, Podzamezer D, Johnson M, Clotet B, Cimoch P, Pozniak A, Richmond G, Schneider S, Arribas J, King M, Marsh T, Naylor C, Tressler R, Bertz R, IAS Conference on HIV Pathogenesis, Paris France
• Preliminary Results of Dosing of Amdoxovir in Treatment-Experienced Patients.
  Thompson, M, Richmond, G, Kessler, H, Bae A, Sorbel J, Sista N, Adda N and Rousseau F, Conference on Retroviruses and Opportunistic Infections, Boston MA
• T-1249 Demonstrates Potent Antiviral Activity over 10 Day Dosing in Most Patients who Have Failed a Regimen Containing Enfuvirtide (ENF): Planned Interim Analysis of T...
  Miralles GD, Lalezari PH, Bellos N, Richmond G, Zhang Y, Murchison H, Spense R, Raskino C, Demasi RA, 10th Conference on Retroviruses and Opportunistic Infections, Boston MA
• A Phase I, randomized, dose- escalation, placebo controlled study of a fully human monoclonal antibody against CCR5 (HGS004) in patients with CCR5 tropic HIV-1 infecti...
  Lalezari J, Lederman M, Yadavalli G, Para M, Richmond G, DeJesus E, Searle J, Cai W, Roschke V, Zhong J, Hicks C, Friemuth W, Subramanian M, 46th ICAAC SanFrancisco
• Efficacy and Safety of APV/RTV 600/100 mg BID Compared to APV 1200 mg BID in ART experienced and naïve subjects: ESS40011.
  Nadler J, Gathe J, Pollard R, Richmond G, Liao Q, Lancaster T, Griffith S, Pappa K, Hernandez J, 14th International AIDS Conference, Barcelona, Spain
• Geotypic (GT) and Virtual Phenotypic (vPT) Correlates of Virologic Response to Abacavir (ABC)-based Therapy in the ZORRO Trial (ESS40009).
  Ruane P, Hernandez J, Richmond G, Williams A, Fralich T, Yau L, Hessenthaler S, Lanier ER, 14th International AIDS Conference, Barcelona, Spain
• Pharmacodynamic effects of zidovudine 600 mg once daily versus zidovudine 300 mg twice daily in therapy-naïve HIV-infected patients (COD20002).
  Ruane P, Richmond G, DeJesus E, Hill-Zabala C, Danehower S, Liao Q, Johnson J, Schaeefer M, 14th International AIDS Conference, Barcelona, Spain
• The Use of Recombinant Human Growth Hormone for Dorsocervical Fat Pad Accumulation in a Patient on Highly Active Antiretroviral Therapy.
  Richmond G, Appleby V, Strawbridge T, Fourteenth Annual Conference Association of Nurses in AIDS Care, Minneapolis, MN
• Safety and Efficacy of Recombinant Human Growth Hormone Serostim® for HIV Associated Wasting in the Era of Highly Active Antiretroviral Therapy.
  Richmond G, Nebiolo L, Rosen A, Finkelstein J, Landy H, Muurahainen, Fourth International Conference on Nutrition and HIV Infection, Cannes, France
• Efficacy and Safety of MDL 28,574A in HIV-Positive Patients with Baseline CD4 Values of 301-500.
  Richmond G, Zolnouni P, Stall J, McPherson M, Hamedani P, Cross V, XI International Conference on AIDS, Vancouver Canada
• Home Infusion Therapy in the Management of HIV Disease using the PAS-Port™ Catheter.
  Richmond G, Appleby V, III Osterreichischen AIDS-Kongress, Vienna, Austria
• Prophylaxis with Inhaled Pentamidine does not Diminish the Yield of Sputum Induction for Diagnosis of Pneumocystis Carinii Pneumonia. 1991 International Conference of ...
  Richmond G, Imoto E, Doherty J, Beck J, Brown J, American Review of Respiratory Diseases
• A Phase II Safety and Efficacy Study of Bevirimat (BMV) in Heavily Treatment Experienced HIV+ Patients Identifies the Target Phase III Study Profile.
  Lalezari J, McCallister S, Gigliotti M, Cohen C, Elion R, Brinson C, Richmond G, Thompson M, Martin D, ICAAC/ISDA
• Intranasal Cryptococcal Nodule with Disseminated Disease.
  Markwart N, Richmond G, Poster presentation Broward General Medical Center Annual Resident Research Competition
• HIV Integrase Resistance and Phenotypic Susceptibility to Dolutegravir (DTG, S/GSK1349572) for Subjects with Virologic Failure on Raltegravir (RAL).
  Cloete B, Katlama C, Soriano V, Lazzarin A, Richmond G, Huang J, Vavro CL, Underwood MR, Ait-Khaled M, Nichols, W, 9th European Workshop on HIV and Hepatitis
• Dolutegravir (DTG, S/GSK1349572) in Subjects with HIV Exhibiting Raltegravir (RAL) Resistance: Functional Monotherapy Results of VIKING Study Cohort II.
  Eron J, Kumar, P, Lazzarin A, Richmond G, Soriano V, Huang J, Vavro C, Ait-Khaled M, Min S, Yeo J, 18th Conference on Retroviruses and Opportunistic Infections
• Activity of Next Generation Integrase Inhibitor (INI)S/GSK1349572 in Subjects with HIV Exhibiting Raltegravir Resistance: Initial Results of VIKING Study (ING112961).
  Eron J, Durant J, Poizot-Martin I, Reynes J, Soriano V, Kumar P, Richmond G, Vittecoq D, Fujiwara T, Ait-Khaled M, Mins, Thomas D, Cuffe R, Yeo J, XVIII International AIDS Conference, Vienna, Austria
• Once Daily S/GSK1379572 as Part of Combination Therapy in Antiretroviral Naïve Adults: Rapid and Potent Antiviral Responses in the interim 16-Week Analysis from SPRING...
  Arribas J, Lazzarin A, Raffi F, Rakhmanova A, Richmond G, Rockstroh J, van Lunzen J, Young B, Almond S, Brothers C, Min S, Nichols G, XVIII International AIDS Conference, Vienna, Austria
• Dolutegravir (DTG, S/GSK1349572) treatment of HIV subjects with raltegravir resistance: viral suppression at Week 24 in the VIKING study.
  Soriano V, Cox J, Eron J, Kumar P, Katlama C, Lazzarin A, Poizot-Martin I, Richmond G, Ait-Khaled M, Fujiwara T, Huang J, Min S, Vavro C, Yeo J, 13th European AIDS Conference, Belgrade Serbia
• Join now to see all